中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
21期
3214-3216
,共3页
射频消融术%肝动脉插管栓塞化疗%肝肿瘤
射頻消融術%肝動脈插管栓塞化療%肝腫瘤
사빈소융술%간동맥삽관전새화료%간종류
Radiofrequency ablation%TACE%Hepatocellular neoplasm
目的:观察射频消融术(RFA)联合肝动脉介入疗法对原发性肝癌(PLC)的有效性和安全性。方法选择 PLC 患者64例,按数字表法随机将64例患者分为两组,观察组和对照组各32例,观察组给予肝动脉插管栓塞化疗(TACE)联合 RFA 治疗,而对照组给予 TACE 治疗。治疗1年后,随访肿瘤缓解情况以及患者1、2、3年累积生存率和两组患者 AST、ALT 和γ-GT 的变化并进行比较。结果治疗1年后,观察组缓解率为71.9%(23/32),对照组为43.8%(14/32),两组缓解率差异有统计学意义(χ2=5.189,P <0.05);观察组1、2、3年累积生存率分别为65.6%(21/32)、65.6%(21/32)、62.5%(20/32),对照组分别为37.5%(12/32)、28.1%(9/32)、21.9%(7/32),两组差异均有统计学意义(χ2=5.067、9.035、10.83,均 P <0.05);治疗2个月后,观察组 AST、ALT 和γ-GT 均明显优于对照组(t =4.218、2.449、8.647,均 P <0.05)。结论RFA联合 TACE 治疗能明显改善 PLC 患者的临床症状,改善患者的肝功能,有助于延长患者生存时间。
目的:觀察射頻消融術(RFA)聯閤肝動脈介入療法對原髮性肝癌(PLC)的有效性和安全性。方法選擇 PLC 患者64例,按數字錶法隨機將64例患者分為兩組,觀察組和對照組各32例,觀察組給予肝動脈插管栓塞化療(TACE)聯閤 RFA 治療,而對照組給予 TACE 治療。治療1年後,隨訪腫瘤緩解情況以及患者1、2、3年纍積生存率和兩組患者 AST、ALT 和γ-GT 的變化併進行比較。結果治療1年後,觀察組緩解率為71.9%(23/32),對照組為43.8%(14/32),兩組緩解率差異有統計學意義(χ2=5.189,P <0.05);觀察組1、2、3年纍積生存率分彆為65.6%(21/32)、65.6%(21/32)、62.5%(20/32),對照組分彆為37.5%(12/32)、28.1%(9/32)、21.9%(7/32),兩組差異均有統計學意義(χ2=5.067、9.035、10.83,均 P <0.05);治療2箇月後,觀察組 AST、ALT 和γ-GT 均明顯優于對照組(t =4.218、2.449、8.647,均 P <0.05)。結論RFA聯閤 TACE 治療能明顯改善 PLC 患者的臨床癥狀,改善患者的肝功能,有助于延長患者生存時間。
목적:관찰사빈소융술(RFA)연합간동맥개입요법대원발성간암(PLC)적유효성화안전성。방법선택 PLC 환자64례,안수자표법수궤장64례환자분위량조,관찰조화대조조각32례,관찰조급여간동맥삽관전새화료(TACE)연합 RFA 치료,이대조조급여 TACE 치료。치료1년후,수방종류완해정황이급환자1、2、3년루적생존솔화량조환자 AST、ALT 화γ-GT 적변화병진행비교。결과치료1년후,관찰조완해솔위71.9%(23/32),대조조위43.8%(14/32),량조완해솔차이유통계학의의(χ2=5.189,P <0.05);관찰조1、2、3년루적생존솔분별위65.6%(21/32)、65.6%(21/32)、62.5%(20/32),대조조분별위37.5%(12/32)、28.1%(9/32)、21.9%(7/32),량조차이균유통계학의의(χ2=5.067、9.035、10.83,균 P <0.05);치료2개월후,관찰조 AST、ALT 화γ-GT 균명현우우대조조(t =4.218、2.449、8.647,균 P <0.05)。결론RFA연합 TACE 치료능명현개선 PLC 환자적림상증상,개선환자적간공능,유조우연장환자생존시간。
Objective To discuss the safety and feasibility of radiofrequency ablation (RFA)combined with transcatheter arterial chemoembolization(TACE)for patients with primary liver carcer(PLC).Methods 64 cases with PLC were selected and randomly divided into two groups,32 cases in each group.The observation group accepted TACE combined with RFA therapy,while the control group only received TACE treatment.Term efficacy (after 1 year)and 1,2,3 -year survival rate were compared in the two groups.The changes of liver function parameters including aspartate aminotransferase (AST),alanine aminotransferase (ALT) and γ-aminoacyl transferase (γ-GT)of the two groups were analyzed and compared.Results After 1 year of treatment,the remission rate was 71.9% (23 /32)in the observation group,which in the control group was 43.8% (14 /32),the difference was statis-tically significant (χ2 =5.189,P <0.05).The 1,2,3 -year cumulative survival rates were 65.6% (21 /32),65.6%(21 /32)and 62.5% (20 /32)in the observation group,which in the control group were 37.5% (12 /32),28.1%(9 /32)and 21.9% (7 /32),the differences were statistically significant (χ2 =5.067,9.035,10.83,all P <0.05). After 2 months of treatment,AST,ALT and γ-GT levels in the observation group were significantly higher than those in the control group(t =4.218,2.449,8.647,all P <0.05).Conclusion TACE combined with RFA therapy can significantly improve the clinical symptoms of patients with PLC,which can improve liver function in patients and help prolong the survival time.